AbbVie Inc stock page - price, fundamentals, dividends - iOCharts

Ticker
ABBV

Price
153.50
Stock movement down
-0.79 (-0.51%)
Company name
AbbVie Inc
Exchange
(NYSE
,
Currency
USD
)
Sector
Healthcare >
Drug Manufacturers-General
Market cap
271.12B
Ent value
391.95B
Price/Sales
4.78
Price/Book
16.65
Div yield
3.67%
Div growth
17.93%
Growth years
9
FCF payout
42.93%
Trailing P/E
21.73
Forward P/E
12.87
PEG
2.63
EPS growth
36.80%
1 year return
31.84%
3 year return
24.90%
5 year return
18.37%
10 year return
-
Last updated: 2022-05-13

BUSINESS INSIGHT

Revenues per Product Category ($M)

Loading...
Company comments

AbbVie was created through a spinoff from Abbott Laboratories in 2013

Humira is the world’s #1 global pharmaceutical product by a large margin

AbbVie acquired Allergan, the maker of Botox in 2020, hence the huge jump in revenues and the change in the segment classifications

Geographic Revenues ($M)

Loading...

DIVIDENDS

Dividend yield - 5y

Loading...
Dividend yield data
Dividend per share5.64
Dividend yield3.67%
Payout frequencyQuarterly
Maximum yield7.32%
Average yield4.65%
Minimum yield2.77%
Discount to avg yield-26.47%
Upside potential-20.93%
Yield as % of max yield50.21%

Yield distribution (inverse percentile) - 5y

Loading...
Yield distribution data
Dividend yield3.67%
Current yield distribution81.75%
Yield at 100% (Min)2.77%
Yield at 90%3.42%
Yield at 80%3.76%
Yield at 50% (Median)4.80%
Yield at 20%5.39%
Yield at 10%5.77%
Yield at 0% (Max)7.32%

Dividend per share

Loading...
Dividend per share data
Years of growth9 years
CCC statusDividend Challenger
Dividend per share5.64
Payout frequencyQuarterly
Ex-div date13 Apr 2022
EPS (TTM)7.02
EPS (1y forward)11.93
EPS growth (5y)36.80%
EPS growth (5y forward)8.27%

Dividend growth

Loading...
Please create a free account or log in to access this chart
Dividend growth data
ABBVS&P500
DGR MR8.46%-16.52%
DGR TTM9.27%4.37%
DGR 3 years13.15%3.88%
DGR 5 years17.93%4.73%
DGR 10 years-8.30%
DGR 15 years-5.82%
Time since last change announced197 days
EPS growth (5y)36.80%
EPS growth (5y forward)8.27%

Payout ratio

Loading...
Please create a free account or log in to access this chart
Payout ratio data
EPS coverageFCF coverage
TTM75.85%42.93%
Average--
Forward47.28%-

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E21.73
Price to OCF11.89
Price to FCF12.30
Price to EBITDA10.96
EV to EBITDA15.85

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales4.78
Price to Book16.65
EV to Sales6.91

FINANCIALS

Per share

Loading...
Per share data
Current share count1.77B
EPS (TTM)7.02
FCF per share (TTM)12.40

Income statement

Loading...
Income statement data
Revenue (TTM)56.73B
Gross profit (TTM)39.44B
Operating income (TTM)18.68B
Net income (TTM)12.48B
EPS (TTM)7.02
EPS (1y forward)11.93

Margins

Loading...
Margins data
Gross margin (TTM)69.53%
Operating margin (TTM)32.94%
Profit margin (TTM)22.00%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash6.10B
Net receivables10.73B
Total current assets26.51B
Goodwill32.30B
Intangible assets73.99B
Property, plant and equipment0.00
Total assets143.21B
Accounts payable22.57B
Short/Current long term debt137.00B
Total current liabilities32.52B
Total liabilities126.93B
Shareholder's equity16.28B
Net tangible assets-92.92B

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)22.81B
Capital expenditures (TTM)761.00M
Free cash flow (TTM)22.05B
Dividends paid (TTM)9.46B

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity76.64%
Return on Assets8.71%
Return on Invested Capital47.57%
Cash Return on Invested Capital84.04%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open153.42
Daily high154.39
Daily low151.90
Daily Volume6.04M
All-time high174.96
1y analyst estimate164.73
Beta0.78
EPS (TTM)7.02
Dividend per share5.64
Ex-div date13 Apr 2022
Next earnings date28 Jul 2022

Downside potential

Loading...
Downside potential data
ABBVS&P500
Current price drop from All-time high-12.27%-15.91%
Highest price drop-48.88%-56.47%
Date of highest drop15 Aug 20199 Mar 2009
Avg drop from high-14.16%-11.33%
Avg time to new high16 days12 days
Max time to new high975 days1805 days
COMPANY DETAILS
ABBV (AbbVie Inc) company logo
Marketcap
271.12B
Marketcap category
Large-cap
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Employees
50000
SEC filings
CEO
Richard Gonzalez
Country
USA
City
North Chicago
Stock type
Common stock
CCC status
Dividend Challenger
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
AbbVie could soon pressure Regeneron in eczema treatment, an analyst said Friday as Regeneron stock hit a ceiling at its 200-day line.
May 13, 2022
Pfizer (PFE) is set to buy migraine drugmaker, Biohaven Pharmaceuticals for $11.6 billion. Bayer (BAYRY) beats Q1 earnings and sales expectations.
May 13, 2022
The ones that pay dividends can deliver especially attractive total returns. With that in mind, here are three dividend stocks you can buy and hold for decades. AbbVie (NYSE: ABBV) offers one of the...
May 13, 2022
AbbVie's (ABBV) Rinvoq achieves statistical significance with its co-primary endpoints of clinical remission and endoscopic response in a late-stage study for Crohn's disease.
May 12, 2022
AbbVie (NYSE: ABBV) will present 46 abstracts across eight types of cancer during the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting (June 3-7) and the European Hematology Associ...
May 12, 2022
AbbVie today announced the 2022-2023 class of recipients of the AbbVie Immunology Scholarship, which provides financial support to students living with chronic, immune-mediated diseases pursuing highe...
May 12, 2022
The FDA grants full approval to Lilly (LLY) and Incyte for COVID-19 in certain hospitalized adults. Olumiant is already authorized for emergency use for this indication since November 2020.
May 12, 2022
These Warren Buffett stocks are helping the Oracle of Omaha be a winner even in a down market. Occidental Petroleum (OXY): It was the best-performing stock in the S&P 500 in the first quarter. Chevron...
May 11, 2022
Is AbbVie stock a buy today with its biggest medicine, Humira, soon to face biosimilar rivals in the U.S.?
May 11, 2022
In this article, we discuss the 15 best income stocks to invest in. You can skip our detailed analysis of these stocks and the current market situation, and go directly to 5 Best Income Stocks To Inve...
May 11, 2022
Next page